FEN1 promotes cancer progression of cholangiocarcinoma by regulating the Wnt/β-catenin signaling pathway.
暂无分享,去创建一个
Zhao Wei | Chengzhan Zhu | B. Dong | L. Kun | Jingyu Cao | Zhaowei Sun | Liu Kui | Feng Yujie | Xie Yuwei
[1] Zhigang Guo,et al. Small-Molecule Inhibitors Targeting FEN1 for Cancer Therapy , 2022, Biomolecules.
[2] Yan Zhou,et al. Inhibition of ClC-5 suppresses proliferation and induces apoptosis in cholangiocarcinoma cells through the Wnt/β-catenin signaling pathway , 2022, BMB reports.
[3] C. Braconi,et al. Metabolic Reprogramming in Cholangiocarcinoma. , 2022, Journal of hepatology.
[4] Yingjian Wang,et al. miR-4324 inhibits ovarian cancer progression by targeting FEN1 , 2022, Journal of Ovarian Research.
[5] Chengzhan Zhu,et al. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma , 2021, Cellular Oncology.
[6] T. Tot,et al. Integrative meta-analysis of gene expression profiles identifies FEN1 and ENDOU as potential diagnostic biomarkers for cervical squamous cell carcinoma , 2021, Oncology letters.
[7] Fuan Wang,et al. Precision Spherical Nucleic Acids Enable Sensitive FEN1 Imaging and Controllable Drug Delivery for Cancer-Specific Therapy. , 2021, Analytical chemistry.
[8] P. Zhou,et al. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy , 2021, Signal Transduction and Targeted Therapy.
[9] Penghui Wang,et al. Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer , 2021, Frontiers in Oncology.
[10] David M. Wilson,et al. FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers , 2021, Cancers.
[11] Wei Wei,et al. Fluorescent Assay of FEN1 Activity with Nicking Enzyme-Assisted Signal Amplification Based on ZIF-8 for Imaging in Living Cells. , 2021, Analytical chemistry.
[12] X. Che,et al. FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis , 2021, Annals of translational medicine.
[13] Lingfeng He,et al. PRMT1 is critical to FEN1 expression and drug resistance in lung cancer cells. , 2020, DNA repair.
[14] R. Kolodner,et al. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination , 2020, Proceedings of the National Academy of Sciences.
[15] C. Mussolino,et al. DNA Damage: From Threat to Treatment , 2020, Cells.
[16] G. Gores,et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management , 2020, Nature Reviews Gastroenterology & Hepatology.
[17] E. Zhao,et al. Flap endonuclease 1 (FEN1) as a novel diagnostic and prognostic biomarker for gastric cancer. , 2020, Clinics and research in hepatology and gastroenterology.
[18] Zujiang Yu,et al. Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma , 2020, Disease markers.
[19] Zhigang Guo,et al. FEN1 inhibitor increases sensitivity of radiotherapy in cervical cancer cells , 2019, Cancer medicine.
[20] Y. Teng,et al. FEN1 mediates miR‐200a methylation and promotes breast cancer cell growth via MET and EGFR signaling , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] Lingfeng He,et al. MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer , 2019, Oncogene.
[22] P. Hu,et al. TGFβ1- miR-140-5p axis mediated up-regulation of Flap Endonuclease 1 promotes epithelial-mesenchymal transition in hepatocellular carcinoma , 2019, Aging.
[23] H. Ansari,et al. Association between the flap endonuclease 1 gene polymorphisms and cancer susceptibility: An updated meta‐analysis , 2019, Journal of cellular biochemistry.
[24] J. Marin,et al. Wnt–β-catenin signalling in liver development, health and disease , 2018, Nature Reviews Gastroenterology & Hepatology.
[25] Kuen-Feng Chen,et al. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. , 2018, European journal of cancer.
[26] Hong Zhu,et al. Synergistic antitumor effect of combined paclitaxel with FEN1 inhibitor in cervical cancer cells. , 2018, DNA repair.
[27] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[28] Michael S. Goldberg,et al. DNA Damage and Repair Biomarkers of Immunotherapy Response. , 2017, Cancer discovery.
[29] Ziheng Zhuang,et al. FEN1 promotes tumor progression and confers cisplatin resistance in non‐small‐cell lung cancer , 2017, Molecular oncology.
[30] T. Bekaii-Saab,et al. Next‐generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance , 2016, Cancer.
[31] E. Swisher,et al. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies , 2016, Clinical Cancer Research.
[32] K. Boberg,et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.
[33] Hiromi Nakamura,et al. Genomic spectra of biliary tract cancer , 2015, Nature Genetics.
[34] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[35] L. Finger,et al. Functional regulation of FEN1 nuclease and its link to cancer , 2010, Nucleic acids research.
[36] G. Gores,et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. , 2000, Cancer research.